Hepion Pharmaceuticals Inc. (NASDAQ: HEPA)
$1.07
-0.0100 ( -0.93% ) 2.0K
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
Market Data
Open
$1.07
Previous close
$1.08
Volume
2.0K
Market cap
$5.80M
Day range
$1.06 - $1.07
52 week range
$0.90 - $9.98
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Feb 21, 2024 |
4 | Insider transactions | 1 | Feb 21, 2024 |
8-k | 8K-related | 14 | Feb 20, 2024 |
8-k | 8K-related | 20 | Feb 16, 2024 |
8-k | 8K-related | 14 | Feb 07, 2024 |
8-k | 8K-related | 14 | Jan 03, 2024 |
8-k | 8K-related | 13 | Dec 07, 2023 |
4 | Insider transactions | 1 | Nov 28, 2023 |
10-q | Quarterly Reports | 71 | Nov 20, 2023 |
nt | Quarterly Reports | 1 | Nov 14, 2023 |